Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca allies with Heptares on GPCR drug research

AstraZeneca allies with Heptares on GPCR drug research

2nd June 2011

AstraZeneca has agreed a new partnership with Heptares Therapeutics that will see the two companies developing drugs targeting G-protein coupled receptors (GPCRs).

The four-year collaboration will utilise innovative technology from Heptares that will allow analysis of the structure of GPCRs, one of the most important protein types in the body, to be conducted in a stable manner for the first time.

Heptares will receive an initial upfront payment of $6.25 million (3.82 million pounds) plus research funding and milestone payments for its part in the research, which will involve discovery teams from both companies.

GPCR targets with potential applications in nervous system/pain, cardiovascular/metabolic and inflammatory disorder treatments will be studied, with AstraZeneca possessing rights to develop any drug candidates arising from the work.

Martin Mackay, president of research and development at AstraZeneca, said: "This exciting collaboration gives us access to cutting-edge technology that will enable us to apply our biophysical and antibody generation capabilities to this important, yet extremely challenging, area of research."

Last month, the company announced that it will also be partnering the Netherlands Cancer Institute on a research collaboration focusing on personalised treatments for colorectal cancer.ADNFCR-8000103-ID-800564770-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.